Company

RegCell

Emeryville, California biotech founded in Osaka in 2016. Engineers regulatory T cells to switch off autoimmune disease.

1 story

Regulatory News has published 1 story about RegCell on 19 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 19 September 2026.

This page is generated from Regulatory News’ editorial coverage of RegCell. It is not an advertisement.

On the record

Company: RegCell, Inc. (privately held)
Headquarters: Emeryville, California; founded in Osaka, Japan
Founded: January 2016
Regulator: Japan’s AMED (grant funder); U.S. FDA (target of the planned IND submission)
Latest milestone: $66 million financing ($44M Series A plus a second AMED grant) to fund an FDA IND submission for its Treg cell therapy platform

Each line is taken from the most recent story of ours that states it.

Our coverage

1 story, newest first.

A woman in a pinstripe blazer at a table with notes and a microphone during a press briefing

Spotlight RegCell Raises $66M for Nobel-Backed Treg Therapy Sep 19, 20266 min read Read the story

All companies